648 related articles for article (PubMed ID: 24034762)
1. [Methylphenidate and secondary Raynaud's phenomenon].
Iglesias Otero M; Portela Romero M; Bugarín González R; Ventura Victoria MA
Semergen; 2013 Sep; 39(6):330-4. PubMed ID: 24034762
[TBL] [Abstract][Full Text] [Related]
2. OROS-Methylphenidate-Induced Raynaud's Phenomenon: A Dose-Related Side Effect.
Bayram Ö; Hergüner S
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):521-2. PubMed ID: 26222712
[No Abstract] [Full Text] [Related]
3. Treatment of Raynaud's phenomenon.
García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Pardo-Santos R; Levy R; Maldonado CG; Chávez GP; Cervera R
Autoimmun Rev; 2008 Oct; 8(1):62-8. PubMed ID: 18692160
[TBL] [Abstract][Full Text] [Related]
4. Raynaud's phenomenon in children.
Ortega Vicente E; Garrido Redondo M
Reumatol Clin; 2016; 12(6):342-344. PubMed ID: 26602360
[TBL] [Abstract][Full Text] [Related]
5. [Rhytidectomy and Raynaud's phenomenon: about two cases].
Nicolas J; Labbé D
Ann Chir Plast Esthet; 2004 Dec; 49(6):564-8. PubMed ID: 15582213
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Raynaud's disease.
Cooke JP; Marshall JM
Vasc Med; 2005 Nov; 10(4):293-307. PubMed ID: 16444858
[TBL] [Abstract][Full Text] [Related]
7. Raynaud's phenomenon: pathogenesis and management.
Bakst R; Merola JF; Franks AG; Sanchez M
J Am Acad Dermatol; 2008 Oct; 59(4):633-53. PubMed ID: 18656283
[TBL] [Abstract][Full Text] [Related]
8. Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: a retrospective case-control study of rheumatology patients.
Goldman W; Seltzer R; Reuman P
Arthritis Rheum; 2008 Feb; 58(2):563-6. PubMed ID: 18240233
[TBL] [Abstract][Full Text] [Related]
9. Raynaud's phenomenon (secondary).
Herrick A
BMJ Clin Evid; 2008 Sep; 2008():. PubMed ID: 19445801
[TBL] [Abstract][Full Text] [Related]
10. Lisdexamfetamine and Secondary Raynaud's Phenomenon.
Gnanavel S
Prim Care Companion CNS Disord; 2018 Sep; 20(5):. PubMed ID: 30256542
[No Abstract] [Full Text] [Related]
11. Recent achievements in the management of Raynaud's phenomenon.
Baumhäkel M; Böhm M
Vasc Health Risk Manag; 2010 Apr; 6():207-14. PubMed ID: 20407628
[TBL] [Abstract][Full Text] [Related]
12. [Calcium antagonists and Raynaud's phenomenon].
Hachulla E; Devulder B
Therapie; 1993; 48 Spec No():707-11. PubMed ID: 8091357
[TBL] [Abstract][Full Text] [Related]
13. [Raynaud's phenomena: diagnostic and treatment study].
Priollet P
Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
[TBL] [Abstract][Full Text] [Related]
14. Difficulties in diagnosis and treatment of severe secondary Raynaud's phenomenon in a Cameroonian woman: a case report.
Agbor VN; Njim T; Aminde LN
J Med Case Rep; 2016 Dec; 10(1):356. PubMed ID: 27998297
[TBL] [Abstract][Full Text] [Related]
15. Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.
Stoyneva Z
Auton Neurosci; 2004 Nov; 116(1-2):62-8. PubMed ID: 15556839
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of erythromelalgia and Raynaud's phenomenon.
Berlin AL; Pehr K
J Am Acad Dermatol; 2004 Mar; 50(3):456-60. PubMed ID: 14988692
[TBL] [Abstract][Full Text] [Related]
17. Vasospasm of the scrotum--a manifestation of Raynaud's phenomenon?
al-Awami M; Schillinger M; Minar E
Vasa; 2004 May; 33(2):87-8. PubMed ID: 15224461
[TBL] [Abstract][Full Text] [Related]
18. [Raynaud's phenomenon: pathogenesis and prevalence].
Mikulska D
Ann Acad Med Stetin; 2010; 56(1):11-4. PubMed ID: 21427808
[TBL] [Abstract][Full Text] [Related]
19. Systemic sclerosis induced by CNS stimulants for ADHD: A case series and review of the literature.
Meridor K; Levy Y
Autoimmun Rev; 2020 Jan; 19(1):102439. PubMed ID: 31734401
[TBL] [Abstract][Full Text] [Related]
20. Raynaud's phenomenon.
O'connor CM
J Vasc Nurs; 2001 Sep; 19(3):87-92; quiz 93-4. PubMed ID: 11533581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
